RoMed Klinikum Rosenheim

The trials here

What the 28 trials at this site are about, from their registry records.

Conditions

• COPD6 trials
• Idiopathic pulmonary fibrosis6 trials
• Ovarian cancer4 trials
• Colorectal cancer3 trials
• Lung cancer3 trials
• Gastric and oesophageal cancer2 trials
• Peripheral artery disease2 trials
• Coeliac disease1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Pancreatic cancer1 trial
• Rheumatoid arthritis1 trial
• and 1 more

Phase

• Phase 318 trials
• Phase 26 trials
• Phase 41 trial

Status

• Completed11 trials
• Recruiting9 trials
• Active, not recruiting7 trials
• Enrolling by invitation1 trial

Lead sponsor

• AstraZeneca4 trials
• United Therapeutics3 trials
• Dominik Paul Modest2 trials
• Sanofi2 trials
• AGO Study Group1 trial
• and 16 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease

  2025-520473-40-00· Phase 2· AstraZeneca AB· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Dominik Paul Modest· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Recruiting

  A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet

  2023-506150-21-00· Phase 2· Dr. Falk Pharma GmbH· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

• Active, not recruiting

  Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  NCT05687266· Phase 3· AstraZeneca· Source

• Active, not recruiting

  SELUTION4SFA Trial

  NCT05132361· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS

  NCT05452213· Phase 4· Institut Für Frauengesundheit GmbH· Source

• Recruiting

  Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

  NCT05009082· Phase 3· AGO Study Group· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Recruiting

  Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

  NCT05007132· Phase 2· Dominik Paul Modest· Source

• Recruiting

  MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  NCT04111978· Phase 3· Swiss GO Trial Group· Source

• Active, not recruiting

  A Study of the Temporary Spur Stent for the Treatment of Narrowing and Blockages in the Arteries Below the Knee

  NCT03807531· ReFlow Medical, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• COPD2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Ovarian cancer2 recruiting
• Coeliac disease1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer

  2023-506882-70-00· Phase 3· H e x a l AG· Source

• Completed

  A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  NCT06208306· Phase 3· Sanofi· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· United Therapeutics· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04751487· Phase 3· Sanofi· Source

• Completed

  PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

  NCT04484636· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

  NCT04375605· Phase 3· Universitätsmedizin Mannheim· Source

• Completed

  CIRCULATE

  NCT04089631· Phase 3· Technische Universitat Dresden· Source

• Active, not recruiting

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· Phase 3· AstraZeneca· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source